Abstract
Polygenic risk scores (PRS) continue to improve with novel methods and expanding genome-wide association studies. Healthcare and third-party laboratories are increasingly deploying PRS reports to patients. Although new PRS show improving strengths of association with traits, it is unknown how the classification of high polygenic risk changes across individual PRS for the same trait. Here, we determined classification of high genetic risk from all cataloged PRS for three complex traits. While each PRS for each trait demonstrated generally consistent population-level strengths of associations, classification of individuals in the top 10% of each PRS distribution varied widely. Using the PRSMix framework, which incorporates information across several PRS to improve prediction, we generated sequential add-one-in (AOI) PRSMix_AOI scores based on order of publication. PRSMix_AOIn led to improved PRS performance and more consistent high-risk classification compared with the PRSn. The PRSMix_AOI approach provides more stable and reliable classification of high-risk as new PRS continue to be generated toward PRS standardization.
Competing Interest Statement
A.C.F. reports being co-founder of Goodpath, serving as scientific advisor to MyOme and HeartFlow, and receiving a research grant from Foresite Labs. J.W.S. is a member of the Scientific Advisory Board of Sensorium Therapeutics (with options), has received grant support from Biogen, Inc. and is PI of a collaborative study of the genetics of depression and bipolar disorder sponsored by 23andMe for which 23andMe provides analysis time as in-kind support but no payments. P.N. reports research grants from Allelica, Amgen, Apple, Boston Scientific, Genentech / Roche, and Novartis, personal fees from Allelica, Apple, AstraZeneca, Blackstone Life Sciences, Creative Education Concepts, CRISPR Therapeutics, Eli Lilly & Co, Esperion Therapeutics, Foresite Labs, Genentech / Roche, GV, HeartFlow, Magnet Biomedicine, Merck, Novartis, TenSixteen Bio, and Tourmaline Bio, equity in Bolt, Candela, Mercury, MyOme, Parameter Health, Preciseli, and TenSixteen Bio, and spousal employment at Vertex Pharmaceuticals, all unrelated to the present work. The remaining authors declare no competing interests.
Funding Statement
This work was supported by grants K08HL161448 (to A.C.F.), R01HL164629 (to A.C.F.), K08HL168238 (to A.P.P.), R01HL169015 (to A.P.P.), R01HL1427 (to P.N.), R01HL148565 (to P.N.), R01HL148050 (to P.N.) from the National Heart, Lung, and Blood Institute and grants T32HG010464 (to S.M.U.), R01HG012354 (to A.P.P.) and U01HG011719 (to A.P.P. and P.N.) from the National Human Genome Research Institute.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional review board of Mass General Brigham gave ethical approval for this work (protocol 2020P001737).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* These authors jointly supervised this work
Data availability
All data are made available from the All of Us Research Study to researchers from universities and other institutions with genuine research inquiries following institutional review board and All of Us approval. This research was approved by the Mass General Brigham institutional review board. The weights of the polygenic scores analyzed in this study are publicly available for download from the Polygenic Score Catalog.20 The mixing weights of the PRSMix_AOIn are available in the supplementary tables 5-7.
